MARKET

NOVN

NOVN

Novan
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.15
-0.41
-4.79%
Opening 14:38 09/20 EDT
OPEN
8.20
PREV CLOSE
8.56
HIGH
8.31
LOW
8.05
VOLUME
143.20K
TURNOVER
--
52 WEEK HIGH
25.90
52 WEEK LOW
4.326
MARKET CAP
153.33M
P/E (TTM)
-3.9275
1D
5D
1M
3M
1Y
5Y
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the Cantor Fit...
GlobeNewswire · 5h ago
NOVN: Syneos Selected as Commercialization Partner
By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT September Update On September 9, 2021, Novan (NASDAQ:NOVN) hosted a corporate update conference call and webcast. The call was led by Novan President and CEO, Paula Brown Stafford, wh...
Zacks Small Cap Research · 6h ago
Tay-Sachs Disease Drugs Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2030
Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region.
AmericaNewsHour · 7h ago
Global Sterile Injectable Drugs Market to Witness Considerable growth throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution channel, and by region.
AmericaNewsHour · 8h ago
Non-Metastatic Castration Resistant Prostate Cancer Treatment Market- Overview by Manufactures,Business Analysis, Opportunity, Industry Growth, and Forecast to 2029
Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029"which delivers detailed overview of the global non-metastatic castration resistant prostate cancer treatment market in terms of market segmentation by therapy typ...
AmericaNewsHour · 8h ago
Global Myeloproliferative Disorder (MPD) Treatment Market to Grow Owing to Rising Prevalence of Myeloproliferative Disorders Among Individuals till 2029
Research Nester released a report titled which delivers a detailed overview of the global myeloproliferative disorder treatment market in terms of market segmentation by type, treatment, end-user, and by region.
AmericaNewsHour · 9h ago
DiGeorge Syndrome Drug Market Propelled by Increased Patient Pool and R&D Initiatives to Witness Substantial GAGR throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the DiGeorge syndrome drug market in terms of market segmentation by therapy type, route of administration, end-user, and by region.
AmericaNewsHour · 9h ago
Growth Hormone Deficiency Market: Company Profiles, Growth Strategy, Developing Technologies, Opportunities and Forecast by Regions till 2028
Research Nester published a report titled  which delivers a detailed overview of the growth hormone deficiency market in terms of market segmentation by application, by route of administration, by distribution channel,  and by region.
AmericaNewsHour · 12h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NOVN. Analyze the recent business situations of Novan through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NOVN stock price target is 42.50 with a high estimate of 72.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 3.99M
% Owned: 21.19%
Shares Outstanding: 18.81M
TypeInstitutionsShares
Increased
8
420.56K
New
16
1.87M
Decreased
3
13.69K
Sold Out
24
404.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.98%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/President/Chief Executive Officer/Director
Paula Stafford
Chief Financial Officer/Vice President - Finance/Controller/Secretary
John Gay
Lead Director/Independent Director
W. Geer
Independent Director
James Bierman
Independent Director
Robert Keegan
Independent Director
John Palmour
Independent Director
Machelle Sanders
Independent Director
Steven Skolsky
No Data
About NOVN
Novan, Inc. is a late clinical-stage biotechnology company. The Company is focused on leveraging its nitric oxide (NO)-based technology platform, NITRICIL, to generate macromolecular new chemical entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases, and various other medical conditions. The Company has clinical-stage dermatology drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208) and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, a topical gel with antiviral properties, for the treatment of molluscum. The Company is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19 and is conducting in-vitro assessments targeting the reduction of viral burden and transmission. The Company is developing NVN4100, an antimicrobial indication for the adjacent companion animal health market.

Webull offers kinds of Novan Inc stock information, including NASDAQ:NOVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NOVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NOVN stock methods without spending real money on the virtual paper trading platform.